Liquid Biopsy Market Analysis Reveals Revolutionary Diagnostic Advances and Growth Potential by 2027: Comprehensive Insights on Cancer Screening, Therapy Selection, and Minimal Residual Disease Detection


Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to ResearchAndMarkets.com's offering.

The medical diagnostics sector is witnessing a transformative phase with the integration of liquid biopsy technologies. A recently published report sheds light on the burgeoning liquid biopsy market and its significant growth trajectory expected through 2023 to 2027. It presents an in-depth analysis of market dynamics across various segments, including cancer types, biomarkers, clinical usages, and geographical landscapes.

Amid the global COVID-19 pandemic, the liquid biopsy market has encountered both challenges and growth accelerations. The report offers a granular examination of the pandemic's impact, delving into the shift in market trends and the consequent pricing and volume fluctuations across different cancer indications.

In the domain of liquid biopsy, technologies like Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), and Exosomes are demystified, allowing stakeholders to comprehend the advancements beyond technical jargon. The report provides valuable insights into the opportunities, challenges, and growth projections for these cutting-edge diagnostic tools. Furthermore, it highlights the scope for routine cancer screenings with the advent of non-invasive blood tests that detect cancer DNA, heralding a new era in cancer diagnostics.

With industry leaders like Illumina contributing significantly to research through initiatives like the Circulating Cell-Free Genome Atlas (CCGA), the market is moving swiftly from a developmental phase to substantial growth stages. The potential for liquid biopsy to eclipse traditional surgical biopsy methods presents significant implications for healthcare, offering less invasive, cost-effective, and quicker diagnostic solutions.

The comprehensive report forecasts the market's evolution over the next five years, providing granular data that includes potential market sizes by country, cancer type, and usage—spanning screening, diagnosis, therapy selection, and recurrence monitoring. It is a critical resource for those looking to understand the intricacies of the market's direction and develop informed investment strategies.

Highlighting the international scope of the liquid biopsy market, the publication features detailed breakouts for 15 countries and 4 regions, addressing notable cancer types such as lung, breast, colorectal, prostate, cervical, among others. It further segments the market analysis by usage categories, which encompass Screening/Early Detection, Diagnostic, Therapy Monitoring, and Recurrence Monitoring.

Market Potential Across Geographic and Cancer-Type Segments

  • Detailed analysis of the liquid biopsy market potential by country and region
  • Breakdown of market dynamics for critical cancer types including lung, breast, colorectal, and prostate
  • Insight into usage segments, emphasizing on screening, diagnostic, and monitoring applications

This extensive report is set to be an invaluable source of data for healthcare professionals, investors, and researchers keen on understanding the future landscape of cancer diagnostics.

Key Topics Covered

  1. Market Guides
    • Liquid Biopsy Market Strategic Situation Analysis
    • Guides for Executives, Marketing, Sales, and Business Development Staff
    • Guide for Management Consultants and Investment Advisors
  2. Introduction and Market Definition
    • Understanding Liquid Biopsy and Its Significance
    • The Sequencing Revolution and Market Definition
    • Perspectives on Healthcare and the IVD Industry
  3. Market Overview
    • Players in the Dynamic Market and Biopsy Usage
    • Current Landscape and Future Trends in Liquid Biopsy Technology
  4. Market Trends
    • Drivers Fueling Market Growth
    • Challenges Limiting Market Expansion
    • Instrumentation, Automation, and Technological Developments
  5. Liquid Biopsy Recent Developments
    • Recent Innovations and Industry Updates Driving Market Momentum
  6. Profiles of Key Players
    • Highlighting Key Companies Leading the Liquid Biopsy Market

Companies Mentioned

  • Abbott Laboratories
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agilent/Dako
  • Amoy Diagnostics Co., Ltd
  • Anchor Dx
  • ANGLE plc
  • Applied DNA Sciences
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Burning Rock
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • CellCarta
  • CellMax Life
  • Cepheid (Danaher)
  • Circulogene
  • Cizzle Biotech
  • Clinical Genomics
  • Cytolumina Technologies Corp
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Dxcover
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fluxion Biosciences
  • Freenome
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Integrated Diagnostics
  • Invitae Corporation
  • Janssen Diagnostics
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc
  • Natera
  • NeoGenomics
  • Novogene Bioinformatics Technology Co., Ltd
  • On-Chip Biotechnologies
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Precision Medicine Group
  • PrecisionMed
  • Predicine
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • Standard BioTools
  • Sysmex Inostics
  • Tempus Labs, Inc
  • Thermo Fisher Scientific Inc
  • Todos Medical
  • Veracyte
  • Volition
  • Vortex Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/s1m317

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data